Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Prior to and Following Nephrectomy in Metastatic Renal Cell Carcinoma
NCT00110344Phase 2Terminated
- Sponsor
- Bayer
- Start
- Nov 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Bayer. Started Nov 2005; status: terminated.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00110344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110344.